Multicenter phase 2 study of topical pimecrolimus for early stage mycosis fungoides
Prof. Pablo Ortiz-Romero
The calcineurin pathway is often activated in mycosis fungoides. Pimecrolimus is a calcineurin inhibitor. The multicenter phase 2 PimTo-MF trial in Spain found that topical pimecrolimus 1% cream twice daily for 16 weeks was safe among patients with early mycosis fungoides. The overall response rate was 56%. Responses were seen in patients with stage IA and stage IB disease, but not in patients with stage IIA disease.
